Melanoma

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…

3 years ago

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

3 years ago

Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume

Customer Cash Receipts (A$'000) Customer Cash Receipts (A$'000)MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”,…

3 years ago

Sensus Healthcare to Host Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 3, 2023

BOCA RATON, Fla., July 26, 2023 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in…

3 years ago

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology…

3 years ago

DermaSensor Presents Study Results on Melanoma Detection in a Medicare Population at American Dermoscopy Meeting

DermaSensor’s Device with FDA Breakthrough Designation Demonstrated 96.2% Sensitivity for Detecting Melanoma in Patients Aged 65 and OlderMIAMI--(BUSINESS WIRE)--DermaSensor Inc.,…

3 years ago

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

SHANGHAI, China, July 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

3 years ago

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC)…

3 years ago

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13th at 2:00 PM ETBERWYN, Pa., July 05, 2023 (GLOBE NEWSWIRE) -- Panavance…

3 years ago

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for…

3 years ago